BAPRAS advises patients on risks of ALCL

20 March 2015

The British Association of Plastic, Reconstructive and Aesthetic Surgeons (BAPRAS) responds to a new study by the French National Cancer Institute which reports a small risk between Anaplastic Large Cell Lymphoma (ALCL) and textured breast implants. 

Nigel Mercer, BAPRAS President and Consultant Plastic Surgeon, said:

“ALCL is a very rare condition but we appreciate there will be patients with implants who will want to seek advice and reassurance from their GPs and surgeons. 

“It is the responsibility of the operating surgeon to ensure that the patient is told verbally and in writing of the risk of ALCL before the procedure so they can make a fully informed decision before going ahead.

“BAPRAS continues to advise that any women with breast implants who experience any sudden unexplained changes, lumps or swelling should speak to their GP or their surgeon urgently. However, we maintain that until any further evidence is presented there is no need to remove breast implants as a matter of course. 

“To help drive patient safety and standards, BAPRAS is working with the Department of Health, iCOBRA (The International Collaboration of Breast Registry Activities), implant manufacturers and providers in the development of a UK breast implant register, which is being piloted at the moment.”

BAPRAS, the British Association of Plastic, Reconstructive and Aesthetic Surgery, is the voice of plastic surgery in the UK. It aims to increase the understanding of the professional specialty and scope of plastic surgery, promoting innovation in teaching, learning and research.

Founded in 1946 (originally as the British Association of Plastic Surgeons), today BAPRAS has over 800 members and is the professional representative body for reconstructive and aesthetic plastic surgeons providing services to patients on the NHS and privately in the UK.